ArticleDiscover oncology2025
Deciphering the oncogenic role of key genes in HNSC: insights from multi-omics and functional studies.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundRecent evidence highlighted head and neck squamous cell carcinoma (HNSC) as a significant health concern, demanding precise clinical management. This study aimed to identify molecular biomarkers, delineate their functions, and assess clinical relevance via bioinformatics analysis and in vitro validation.
methodsUsing the GSE58911 microarray dataset, we identified differentially expressed genes (DEGs) meeting the criteria of "|log2 fold change (FC) |≥ 1 and false discovery rate (FDR) < 0.05". Subsequently, the top four hub genes were identified based on the degree method. Expression and functional analyses were conducted to explore their roles in tumorigenesis. RT-qPCR and bisulfite sequencing validated hub gene expression in HNSC cell lines.
resultsFrom the GSE58911 dataset, 1781 differentially expressed genes (DEGs) were identified, with 250 selected for further hub gene analysis. STRING and Cytoscape analyses revealed a protein-protein interaction (PPI) network with 122 nodes and 976 edges. MCODE analysis identified a key module with 28 nodes, and Cytohubba analysis highlighted MAPK3, MLLT4, PLAU, and SERPINE1 as top hub genes. Expression profiling in the TCGA-HNSC dataset showed significantly lower MAPK3 and MLLT4, and higher PLAU and SERPINE1 levels in HNSC samples compared to normal tissues. Validation using additional TCGA cohorts confirmed these findings and associated the dysregulation of these hub genes with poor prognosis. Methylation analyses indicated high levels of MAPK3 and MLLT4 methylation, and low levels of PLAU and SERPINE1 methylation in HNSC tissues. Genetic alterations analysis revealed mutations and amplifications, correlating with poorer overall survival. Subcellular localization studies showed distinct protein localizations, and IHC revealed altered protein expression levels. Immune cell infiltration analysis indicated associations between hub gene expression and immune cell types. Drug prediction analysis suggested potential therapeutic interventions, and functional assays in HNSC cell lines demonstrated that PLAU and SERPINE1 knockdown reduced malignancy traits.
conclusionIn conclusion, MAPK3, MLLT4, PLAU, and SERPINE1 emerge as promising biomarkers and therapeutic targets for HNSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.